Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both
2010
Abstract
We evaluated whether erectile dysfunction (ED) is predictive of mortality and cardiovascular outcomes, and because inhibition of the renin-angiotensin system in high-risk patients reduces cardiovascular events, we also tested the effects on ED of randomized treatments with telmisartan, ramipril, and the combination of the 2 drugs (ONTARGET), as well as with telmisartan or placebo in patients who were intolerant of angiotensin-converting enzyme inhibitors (TRANSCEND). ED is a potent predictor of all-cause death and the composite of cardiovascular death, myocardial infarction, stroke, and heart failure in men with cardiovascular disease.
Trial treatment did not significantly improve or worsen ED.